Vitrakvi 100 mg Alternative – Larocent (Larotrectinib) 100 mg Capsule | Incepta Pharmaceuticals
Larocent 100 mg (Larotrectinib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Vitrakvi (Bayer).
Pack: 12 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Product Overview
Larocent 100 mg is listed in the supplied Lucent product catalogue. Its proposed active ingredient is Larotrectinib, in capsule form. Manufacturer-specific composition is pending verification; do not rely on this listing for dispensing.
Larocent vs Vitrakvi – Reference Brand Comparison
Vitrakvi is a recognized reference brand associated with Bayer. Larocent is listed on the supplied Lucent products price sheet, attributed by the customer to Incepta Pharmaceuticals Ltd. Matching an active ingredient does not demonstrate bioequivalence, regulatory approval or permission to substitute.
Composition and Product Details
- Listed brand: Larocent
- Generic: Larotrectinib (pending manufacturer confirmation)
- Strength: 100 mg
- Dosage form: Capsule
- Catalogue pack: 12 capsules
- Attributed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Therapeutic Uses and Indications
Larotrectinib is used in selected NTRK fusion-positive solid tumors. These are generic-medicine contexts, not independently confirmed approvals for this particular branded presentation. Exact eligible conditions, biomarkers and combination therapies must be confirmed from the local authorized label.
Mechanism of Action
Larotrectinib inhibits TRK proteins produced by NTRK gene fusions. Individual treatment response depends on the disease, formulation, dosing and patient factors.
Dosage and Administration
The stated 100 mg refers to the strength of the supplied product, not a recommended daily or treatment dose. Administration schedules, preparation, food instructions and monitoring depend on the approved indication and formulation. Use only the dose and schedule prescribed by a qualified clinician. Never change strength or substitute a brand without medical advice.
Contraindications
Contraindications can include hypersensitivity and other medicine-specific conditions. Review the current prescribing information for all absolute restrictions, including relevant pregnancy-related contraindications.
Warnings and Precautions
Potential serious risks and monitoring requirements vary by medicine. Discuss infections, cardiovascular disease, liver and kidney function, other medications and pregnancy plans with the specialist. The official product leaflet determines the required safety monitoring.
Possible Side Effects
Adverse reactions may involve gastrointestinal symptoms, fatigue, laboratory abnormalities, infections or organ-specific toxicity, depending on the active ingredient. The full medicine-specific adverse effect profile, frequency and emergency warning signs must be reviewed in the authorized prescribing information.
Drug Interactions
Prescription drugs, nonprescription medicines, herbal products and some foods may interact with Larotrectinib. A pharmacist or specialist should review all current medicines before treatment.
Pregnancy and Breastfeeding
Some treatments can cause fetal harm or require interruption of breastfeeding. Consult the product-specific label and treating specialist for pregnancy testing, contraception and breastfeeding guidance.
Storage and Handling
Follow the temperature, light protection, cold-chain and handling requirements printed on the actual pack. Do not assume storage conditions from another brand or formulation.
Why Is Larocent Listed as an Alternative to Vitrakvi?
The comparison is provided for product discovery by active ingredient and reference brand. It does not establish pharmaceutical or therapeutic equivalence, biosimilarity, interchangeability or authorization in any country.
Manufacturer Information
Listed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Reference brand: Vitrakvi
Reference company: Bayer
Generic: Larotrectinib
Strength: 100 mg
Pack: 12 capsules
Frequently Asked Questions
What does Larocent contain?
Larotrectinib 100 mg, subject to confirmation against the official brand-specific label.
Is Larocent the same as Vitrakvi?
No automatic equivalence or interchangeability can be inferred from the generic ingredient alone.
Can I use another strength instead?
Only when an authorized clinician specifically directs it.
Is a prescription required?
Yes. Appropriate prescription and specialist supervision are required.
Important Medical Disclaimer
Educational product identification only. Clinical information and product availability require verification against official labeling and destination-country regulatory requirements. No purchase or treatment decision should be based on this page alone.
| Generic Name | Larotrectinib |
|---|---|
| Strength | 100 mg |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Pack Size | 12 capsules |
Related products
Casodex 50 mg Alternative – Calupros (Bicalutamide) 50 mg Tablet | Everest Pharmaceuticals
Calupros 50 mg (Bicalutamide) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Casodex (AstraZeneca). It belongs to the nonsteroidal antiandrogen class and is used in selected prostate cancer hormonal treatment regimens.
Active ingredient: Bicalutamide
Strength: 50 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Gleevec / Glivec 100 mg Alternative – Imaxen (Imatinib) 100 mg Tablet | Everest Pharmaceuticals
Imaxen 100 mg (Imatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Gleevec / Glivec (Novartis). It belongs to the BCR-ABL/KIT/PDGFR kinase inhibitor class and is used in selected chronic myeloid leukemia and gastrointestinal stromal tumor settings.
Active ingredient: Imatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Ibrance 125 mg Alternative – Palboxen (Palbociclib) 125 mg Capsule | Everest Pharmaceuticals
Palboxen 125 mg (Palbociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Ibrance (Pfizer). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Palbociclib
Strength: 125 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lynparza 150 mg Alternative – Olanib (Olaparib) 150 mg Tablet | Everest Pharmaceuticals
Olanib 150 mg (Olaparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lynparza (AstraZeneca / MSD). It belongs to the PARP inhibitor class and is used in selected ovarian, breast, pancreatic and prostate cancers.
Active ingredient: Olaparib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Retevmo / Retsevmo 40 mg Alternative – Selcaxen (Selpercatinib) 40 mg Capsule | Everest Pharmaceuticals
Selcaxen 40 mg (Selpercatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Retevmo / Retsevmo (Eli Lilly). It belongs to the RET inhibitor class and is used in selected RET-altered lung or thyroid cancers.
Active ingredient: Selpercatinib
Strength: 40 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tabrecta 200 mg Alternative – Capmaxen (Capmatinib) 200 mg Tablet | Everest Pharmaceuticals
Capmaxen 200 mg (Capmatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tabrecta (Novartis). It belongs to the MET inhibitor class and is used in selected MET exon 14 skipping non-small cell lung cancer.
Active ingredient: Capmatinib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Xalkori 250 mg Alternative – Alkixen (Crizotinib) 250 mg Capsule | Everest Pharmaceuticals
Alkixen 250 mg (Crizotinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xalkori (Pfizer). It belongs to the ALK/ROS1 kinase inhibitor class and is used in selected ALK-positive or ROS1-positive non-small cell lung cancer.
Active ingredient: Crizotinib
Strength: 250 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Zejula 100 mg Alternative – Niranib (Niraparib) 100 mg Capsule | Everest Pharmaceuticals
Niranib 100 mg (Niraparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zejula (GSK). It belongs to the PARP inhibitor class and is used in selected ovarian cancer maintenance treatment settings.
Active ingredient: Niraparib
Strength: 100 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.